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Background: The use of placebo comparisons for randomised trials assessing the efficacy of surgical
interventions is increasingly being considered. However, a placebo control is a complex type of
comparison group in the surgical setting and, although powerful, presents many challenges.
Objectives: To provide a summary of knowledge on placebo controls in surgical trials and to summarise
any recommendations for designers, evaluators and funders of placebo-controlled surgical trials.
Design: To carry out a state-of-the-art workshop and produce a corresponding report involving key
stakeholders throughout.
Setting: A workshop to discuss and summarise the existing knowledge and to develop the new guidelines.
Results: To assess what a placebo control entails and to assess the understanding of this tool in the
context of surgery is considered, along with when placebo controls in surgery are acceptable (and
when they are desirable). We have considered ethics arguments and regulatory requirements, how a
placebo control should be designed, how to identify and mitigate risk for participants in these trials,
and how such trials should be carried out and interpreted. The use of placebo controls is justified in
randomised controlled trials of surgical interventions provided that there is a strong scientific and
ethics rationale. Surgical placebos might be most appropriate when there is poor evidence for the
efficacy of the procedure and a justified concern that results of a trial would be associated with a high
risk of bias, particularly because of the placebo effect.
Conclusions: The use of placebo controls is justified in randomised controlled trials of surgical
interventions provided that there is a strong scientific and ethics rationale. Feasibility work is
recommended to optimise the design and implementation of randomised controlled trials. An outline
for best practice was produced in the form of the Applying Surgical Placebo in Randomised Evaluations
(ASPIRE) guidelines for those considering the use of a placebo control in a surgical randomised
controlled trial.
Limitations: Although the workshop participants involved international members, the majority
of participants were from the UK. Therefore, although every attempt was made to make the
recommendations applicable to all health systems, the guidelines may, unconsciously, be particularly
applicable to clinical practice in the UK NHS.
Future work: Future work should evaluate the use of the ASPIRE guidelines in making decisions about
the use of a placebo-controlled surgical trial. In addition, further work is required on the appropriate
nomenclature to adopt in this space.
Funding: Funded by the Medical Research Council UK and the National Institute for Health Research
as part of the Medical Research Council–National Institute for Health Research Methodology
Research programme.
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ASPIRE Applying Surgical Placebo in
Randomised Evaluations
CSAW Can Shoulder Arthroscopy Work?
DITTO deconstruct, identify, take out,
think, optimise
KORAL Knee Osteoarthritis: Role of
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MRC Medical Research Council
NIHR National Institute for Health
Research
PPI public and patient involvement
QALY quality-adjusted life-year
RCS Royal College of Surgeons
RCT randomised controlled trial
SUcceSS SUrgery for Spinal Stenosis
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What was the research about?
One of the best ways to prove that a new medicine really works is to use a scientific test called a
‘placebo-controlled trial’. In this type of test, half of the participants are given a new pill and the other
half are given a ‘placebo’, which is a dummy pill (usually a sugar pill) that is made to taste and look the
same as the active pill, but has no active ingredients. The results are then compared.
Just like medicines, new surgical procedures need to be tested to show that they are safe and benefit
patients. Ideally, they would also be tested using the ‘placebo-controlled trial’ approach, but asking
patients to have ‘dummy’ surgery is not the same as asking people to take a dummy pill. Placebo
surgery raises lots of ethics questions and is controversial. As it is controversial, guidelines are needed
to recommend when placebo surgery studies can be used (if at all) and what special considerations
need to be taken into account. Our research team was commissioned to develop these guidelines.
What did we do?
We summarised, to the best of our knowledge, all previous research that had used placebo surgery and
reviewed all the ethics literature on this topic. We also looked at the latest scientific understanding of
how placebos work.
We then held a workshop to discuss and summarise the existing knowledge and to develop the new
guidelines. This involved an international team of patients, surgeons, researchers, ethicists,
psychologists, physiologists and funders.
We published the guidelines [i.e. the ASPIRE (Applying Surgical Placebo in Randomised Evaluations)
guidelines] in an influential medical journal and also wrote several other publications. This report
provides a slightly more detailed version of our findings and recommendations.
Who will this help?
The guidelines will help researchers and doctors know when, and how, to best design placebo surgery
studies in the future.
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Placebo comparisons are increasingly being considered for randomised trials assessing the efficacy of
complex interventions, including surgery. A placebo control is a complex type of comparison group and,
although powerful, presents many challenges in a surgical setting.
Aim
The aim of this workshop and report was to extract and summarise the current knowledge on the
use and appropriateness of placebo controls for surgical trials. It was intended to provide advice for
researchers, clinicians, patients and funders when considering or designing a placebo surgical study or
involvement in such a study.
Structure and content of report
This report outlines the background to placebo control for surgery and what a placebo surgical control
entails and provides a summary of the up-to-date understanding of the placebo phenomenon in the
context of surgery. Placebo controls for surgical evaluation are not always acceptable, nor are they
always the most desirable or optimal option. The nature of surgical placebo is explored in terms of
ethics arguments and regulatory requirements. The design of a placebo surgical control is also complex
and consideration is given to this with clear guidelines on process. As placebo surgery is not without
risk, methods are outlined on how to identify and mitigate risk for participants in placebo-controlled
surgical trials. Last, attention is given as to how the results of such trials should be interpreted.
Findings
The use of a placebo control for the evaluation of a surgical procedure is justified provided that a
strong scientific and ethics rationale can be provided. Feasibility work is recommended to explore the
value of placebo randomised controlled trial (RCT) design and optimise the conduct. The workshop and
ensuing publications provide an outline for best practice in the form of the ASPIRE (Applying Surgical
Placebo in Randomised Evaluations) guidelines.
Conclusions
The guidelines are advised reading for those considering the use of a placebo control in a surgical RCT.
Outputs
The workshop has, to date, produced three substantial publications in high-impact journals, and the
content of each helps to guide placebo control comparison and trial design in surgical trials [Beard DJ,
Campbell MK, Blazeby JM, Carr AJ, Weijer C, Cuthbertson BH, et al. Considerations and methods for
placebo controls in surgical trials (ASPIRE guidelines). Lancet 2020;395:828–38; Cousins S, Blencowe NS,
Tsang C, Chalmers K, Mardanpour A, Carr AJ, et al. Optimizing the design of invasive placebo
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Chapter 1 Introduction and background
A preliminary and over-riding ethos for this work is that surgical interventions must be fullyevaluated before being introduced into clinical practice, including existing interventions without
compelling evidence to underpin their use. The present gold standard for such evaluation of clinical
efficacy remains the randomised controlled trial (RCT) using a comparator treatment or group.
Furthermore, using a placebo control is often thought as the ‘best’ trial design approach to investigate
health-care interventions, as it minimises the risk of bias. Such bias can arise from several sources,
including expectation bias and confirmation bias, and could undermine the validity of a comparative
study’s findings. The use of a surgical placebo control is, understandably, highly controversial for ethics
and trial design reasons.The construction or development of a placebo surgical intervention, the achievement
of satisfactory participation/acceptance by surgeons and other key personnel (e.g. anaesthetists), the
participation of patients, and the interpretation of the trial results can all be challenging.
It could be argued that placebo designs are especially important for surgery for two main reasons.
First, surgical interventions have undergone far less rigorous evaluation than drug treatments.1 Second,
bias is particularly high, with surgical interventions anticipated to have a larger placebo effect than
other treatments, given the orchestration and personalisation around the intervention delivery. Recent
work has shown the substantial magnitude and duration of surgical placebo effects.2,3
Placebo trials in surgery can be, and have been, carried out in a number of circumstances.2–6 It is crucial
that triallists, patients and surgeons understand the circumstances in which a surgical placebo control
could or should be used and, if this is to be used, what type of placebo control would be appropriate.
There is a need for clear advice to aid triallists, funders, patients, journal editors and regulators.
Previous reviews of placebo-controlled surgical trials3–6 have examined the characteristics of such studies,
and have raised issues related to recruitment and feasibility, impact on outcome and serious adverse
events.7,8 These reviews, however, have not considered, in detail, trial design issues, such as when it is
appropriate to use a placebo control in a surgical trial, what factors should guide the choice of a placebo
design and how that choice influences intervention standardisation (and fidelity assessment)9 and the
selection and use of co-interventions. Further practical consideration of the ethics implications is needed.10,11
How placebo comparators are developed and piloted before use in a main trial has also not been considered.
Beyond placebo analgesia studies using neuroimaging, there is little supporting information on the
neurophysiological effects of placebo. Trial conduct specifically for placebo-controlled surgical trials has
received little focus, with key areas including qualitative aspects and recruitment. Guidelines around
core methodological considerations are urgently required to ensure that triallists can design (and
funders can appropriately assess and fund) the optimal placebo-controlled surgical trials of the future.
This report comes out of a project funded by the National Institute for Health Research (NIHR) and
the Medical Research Council, which brought together leading national and international experts
to produce state-of-the-art thinking and knowledge on placebo controls in surgical evaluation. The
expert interdisciplinary team of triallists, surgeons, anaesthetists, methodologists and ethicists all
had a strong track record of successful research in this field, including surgical placebo-controlled
trials. The work also brought together four of the leading UK centres of excellence in surgical trial
design and methodology (i.e. Oxford, Bristol, Birmingham and Aberdeen). The study group provided
strength and depth in the design and conduct of surgical trials, ethics expertise, organisation of
consensus workshops, development of trials methodology guidelines and a deep awareness of the
clinical, regulatory and practical trial contexts in which guidelines will be applied. The group also has
extensive active collaborations with practising surgeons and key stakeholders in the UK and overseas
[i.e. the Royal Colleges of Surgeons (RCS) of England (London, UK), Scotland (Edinburgh, UK) and
Ireland (Dublin, Ireland), the Royal Australasian College of Surgeons (East Melbourne, VIC, Australia)
and the American College of Surgeons (Chicago, IL, USA)].
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The output is a set of methodological guidelines, known as the ASPIRE (Applying Surgical Placebo in
Randomised Evaluations) guidelines, to inform the future design of surgical trials and, specifically,
the role and optimal design of placebos in surgical trials.
The structure of the report consists of seven relatively brief, but discursive, elements:
1. What is ‘placebo’ in the context of surgical trials?
2. The current regulatory requirements for placebo-controlled surgical trials.
3. Systematic literature review update for placebo-controlled surgical trials.
4. Ethics considerations for placebo-controlled surgical trials.
5. Design aspects of placebo-controlled surgical trials.
6. Trial conduct and recruitment in surgical trials.
7. Interpretation of placebo-controlled surgical trials and changing practice.
The salient aspects are then given in point form in:
8. Summary guidelines for researchers, reviewers and funders (i.e. the ASPIRE guidelines).
The methodology for translation of the pre-workshop work and workshop proceedings into guidelines
was as follows.
The results from the preparatory work were collated and summarised. This included an updated
systematic review of placebo-controlled surgical trials, extension of a previously published surgical
taxonomy to allow the characterisation and optimisation of aspects of placebo controls, and a scoping
review of regulatory guidance on placebos and collation of up-to-date literature on ethics, methods and
conduct of placebo-controlled surgical trials.
The transcripts of the workshop and the facilitator/rapporteur notes taken at each session formed the
documentary and evidence sources available and informed the final guidelines. Each session subteam
contributed and reviewed the transcripts and notes from their sessions using emergent themes for
integration into the final guidelines. A draft of the guidelines was circulated to the workshop attendees
for feedback and to ensure international generalisability of recommendations.
The work has now been published,12 and the authors and relevant stakeholders have been approached
to ensure that the guidelines meet their needs.
Public and patient involvement
Public and patient involvement (PPI) was important for the workshop from its inception. Following the
NIHR call for a workshop, the submission team was selected from a group of appropriate international
experts, scientists and clinicians. A PPI member (DF-H) was part of the submission team and contributed
to all PPI work and submission documents. On award, a further PPI attendee was invited to the workshop.
This PPI attendee had experience and understanding of placebo-controlled surgical trials. Both patient
representatives had been involved in the CSAW (Can Shoulder Arthroscopy Work?) placebo-controlled
surgical trial13 from Oxford. One patient, who had previously undergone decompression shoulder surgery,
had been the patient representative on the Trial Steering Committee for CSAW. The other patient had
been an enrolled patient on the same trial.
Public and patient involvement members were involved in all stages of the work. Both members
attended the workshop and contributed substantially to discussions from a patient perspective and,
based on their involvement in similar previous trials, also as knowledgeable individuals on aspects of the
methodology. The chairperson made every effort to include the PPI members on most discussion points.
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The PPI members also provided a presentation alongside the other scientific presentations being
delivered. Both members participated in report writing and editing content. Chapter 8, Placebo-
controlled surgical trials: the patient’s perspective, has a section dedicated to the ‘patients’ perspective’,
written by the PPI members. This exemplifies the impact and dissemination features of the PPI input.
It may have been useful to have a further PPI representative outside the Oxford group or perhaps
from overseas, but travel costs were considered in relation to the extra benefit.
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Chapter 2 What is ‘placebo’ in the context
of surgical trials?
The origin of the word ‘placebo’ is from the Latin placere, ‘to please’.
Various definitions of placebo exist, including a medicine or procedure prescribed for the psychological
benefit to the patient rather than for any physiological effect, and a substance that has no therapeutic
effect and is used as a control in testing new drugs.
There is an important distinction between the known placebo effects within established treatment and
those that are formally, and somewhat artificially, devised for evaluation purposes, as per control in a
clinical trial. This document refers to ‘placebo’ in the context of evaluation purposes (in surgery) only.
Early distinctions must also be made between the classical (pharmacological)-derived definitions
and those modified for placebo-controlled evaluations of surgery. Definitions for placebo surgical
intervention vary from ‘a surgical intervention with theoretically little benefit’ to ‘sham’ surgery or
‘placebo surgical intervention’, a procedure in which presumed ‘active’ components of the procedure or
the critical surgical element were removed. Many of these terms are used interchangeably and often
without an ascribed clear meaning. After consideration, the word ‘placebo’ for surgical evaluation has
been used in the report along with the concept of a ‘critical surgical element’.
Further distinction is observed between a completely ‘sham’ or ‘dummy’ treatment (i.e. an entirely
pretend surgery or small superficial incision only) and varied levels of placebo ‘intervention’ in which
some part of the surgery is delivered, with or without additional known benefit. However, rather
than ascribing hard boundaries, a concept in which the placebo intervention is described in levels of
fidelity14 to the complete surgical intervention may be helpful. A placebo intervention can be either
low fidelity [i.e. there is little similarity with the complete surgical intervention (sham surgery being a
category of overall least fidelity)] or high fidelity (i.e. the surgical intervention has most components of
the complete treatment, but perhaps without the presumed active or critical component). The complete
treatment (no placebo) has full fidelity. A schema is given in Table 1, which can also be used in cross-
reference to the DITTO (deconstruct, identify, take out, think, optimise) method for deconstruction,
as reported in Chapter 7.15
The nomenclature is important. Although all placebo-based interventions (in a surgical trial) have some
form of intentional ‘deception’ to support the methodology (i.e. where knowledge of the intervention
received is kept hidden), patient representatives have expressed uneasiness with this descriptor.
Likewise, terms such as ‘magic’ and ‘simulated surgery’ are considered inappropriate. ‘Sham’, although
much used as a descriptor (scientifically), is also considered unacceptable to use with patients because
of its negative connotations with regard to quality of clinical practice/caregivers.
TABLE 1 Levels of fidelity to the complete surgical intervention for placebo-controlled surgical trial design
Fidelity level Descriptor
Index procedure Complete surgical intervention (not placebo)
Placebo: high fidelity Near-complete attributes of the procedure under investigation
Placebo: low fidelity Few attributes of the procedure under investigation
Placebo: minimal fidelity Minimum or no attributes of the procedure under investigation
(i.e. sham, skin incisions only)
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Chapter 3 The psychological and physiological
aspects of placebo for surgical trials
The psychological aspects of placebo
Classical definitions of placebo can introduce conceptual confusion rather than clarity when considering
the mechanisms underpinning placebo effects. For example, defining placebos as inert substances leads
one paradoxically to define placebo effects as the effects of inert substances. These difficulties may stem
from a focus on placebo as a substance rather than placebo as a process.16 Indeed, current definitions
now invoke notions of process. For example, placebo effects have been defined as changes in a person’s
health status that result from the meaning and hope that the person attributes to a procedure, event or
interaction in a health-care setting.17,18 Colloca,19 a leading commentator on the placebo phenomenon,
goes further in linking placebo effects to a specific mechanism, defining them as ‘powerful determinant[s]
of health outcomes across many different diseases and encounters; the placebo effect is due to the
expectancy of positive treatment outcomes’.19
Two main theories dominated early work on the psychological mechanisms underpinning placebo
effects: (1) learning theory, specifically conditioning (i.e. placebo effects are underpinned by associative
learning when placebos are paired with an active drug that triggers a physiological response); and
(2) response expectancy theory (i.e. placebo effects are underpinned by the patient’s conscious or
unconscious expectation that the placebo will have a particular effect). Experiments were designed
to test competing hypotheses derived from these theories and the evidence amassed suggested that
both conditioning and expectancy were involved in placebo effects in different circumstances.20
Less divisive accounts of placebo mechanisms have now been proposed. Benedetti21 emphasises the
importance of considering disease- or system-specific placebo mechanisms, particularly when considering
mechanisms at the physiological level. Colloca and Miller22 integrate insights from learning theory and
response expectancy theory, arguing that patient expectations are the central psychological mechanism
that mediates placebo effects. According to this model, the brain decodes the psychosocial context,
formulating (conscious or unconscious) expectations about outcome that then trigger placebo responses.
Colloca and Miller22 drew on previous work to suggest that expectations are shaped by learning
mechanisms around three types of sign (or triggers) in the psychosocial context:
1. indices, which generate expectations through sensory- or memory-based associations for individuals
(e.g. tablets can be indices when patients become conditioned to expect symptomatic benefit from
taking them)23
2. symbols, which generate expectations through culturally specific conventions, including language
(e.g. the ritual and doctor–patient communication around surgery and the operating theatre foster
particular expectations of benefit)24
3. icons, which generate expectations through perceived similarities with the object (e.g. observing a
similar person with similar symptoms responding to an intervention can foster positive expectations
through social learning mechanisms).25
Understanding the influence of these different elements on placebo effects within clinical trials can
then inform attempts to design, manipulate and control placebo effects in surgery trials.
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Five domains of the psychosocial context of health care that may influence patient outcomes have
been suggested from reviews of the literature.26 A recent review further explored how each of the five
contextual domains are at play in clinical trials and identified specific design features and methods that
might shape patient expectations and, therefore, placebo effects in trials27 (Table 2).
Qualitative research methods are helpful for exploring the psychosocial context of clinical trials and
understanding the myriad influences and dynamic processes involved in shaping patients’ expectations.
For example, interviews in a placebo-controlled trial28 of acupuncture for osteoarthritis revealed that
participants derived empathy not only from the acupuncturists themselves, but also from other trial
personnel, from the friendly and polite reception staff and from the ease of making convenient
appointments, all of which made the patients feel cared for.
How patients are informed about placebo surgery might be a key component of the psychosocial
context of clinical trials that could shape patients’ expectations. Patient information leaflets in placebo-
controlled trials typically seem to explain placebo effects in quite negative terms, if at all, with most
devoting considerable space to describing the potential benefits and mechanisms of action of the trial
treatment while describing placebos as ‘a ‘dummy treatment, which looks like the genuine medicine but
contains no active ingredient’.29 This is important because, arguably, it does not adequately inform
patients about the potential for positive or negative outcomes from the placebo intervention.29
Another acupuncture trial,30 this time for irritable bowel syndrome, identified four main ways that patients
conceptualised placebo effects: (1) placebos are necessary for research, (2) placebo effects are fake,
(3) placebo acupuncture is not real acupuncture and (4) placebos have real effects mediated by
psychological mechanisms. Negative views of placebos as fakes or illusory are potentially problematic
for patients who receive a placebo intervention and experience real tangible benefit from it, as they
may then struggle to make sense of this and integrate it into a coherent narrative that does not entail
them feeling tricked or gullible.30,31
Patient expectations are central to placebo effects and are driven by multiple components of the
psychosocial context, including interpersonal interactions with clinicians and trial personnel, and
information about the trial interventions. It is important to consider this when designing and
conducting placebo-controlled trials in surgery.
TABLE 2 Different domains of the psychosocial context of health care on the surgical placebo response26,27
Domain context;
Characteristics of Placebo-surgery relevant examples influencing the placebo response
Treatment A placebo-surgical control treatment that is very similar in characteristics to the
definitive procedure
Health-care setting A placebo-surgical procedure conducted in the same setting (i.e. an operating theatre),
with all the associated cues
Clinician The perceived status of the practitioners (surgeons, nurses) performing the placebo
surgery in surgical gowns
Patient Previous experience of undergoing surgery
Patient–clinician interaction A previous interaction with the patient
Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C, Cuthbertson BH, et al.,
Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines), pp. 828–38, Copyright (2020),
with permission from Elsevier.12
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The physiological aspects of placebo
The scientific overlap between the physiological and psychological aspects of placebo is significant and
far from straightforward. Most work has been completed in the context of pain and pain relief, rather
than methodological considerations for comparative groups in surgical trials. Therefore, direct application
has limitations. However, in the context of pain modulation, it is well established that the mechanisms
of placebo analgesia involve the antinociception brainstem pathway and spinal inhibition.32 Functional
magnetic resonance imaging work has also linked observed placebo effects to the anticipation of
reward.33 If these effects are substantial for an intervention such as surgery, it is critical that they are
taken account of in any trial design to enable fair comparison or deeper understanding of mechanism.
Furthermore, there is evidence from investigations of the mesolimbic reward system that certain
personalities are more susceptible to such analgesic responses and placebo effects.34 Many of the more
qualitative features of placebo (e.g. expectancy, prior experience and belief systems) can influence
various opioid and dopamine receptor systems to produce an effect,35 giving physiological credence to
centuries-old medical teaching (Galen) regarding the need for ‘confident’ physicians. The therapeutic
setting can also produce very similar physiological changes using the same pathways.35 What should
not be forgotten is that the powerful antinociceptive or positive effects can also be mirrored with
negative expectancy and ‘anxiety amplification’, the understanding of which continues to be driven by
rapidly developing functional magnetic resonance imaging research.36 Such nocebo or negative placebo
effects also have a place in clinical trial design, depending on the research question being asked. It is
likely that with large data set and machine learning input our understanding of these physiological
areas will increase.
DOI: 10.3310/hta25530 Health Technology Assessment 2021 Vol. 25 No. 53
Copyright © 2021 Beard et al. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the
title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
9

Chapter 4 The current regulatory
requirements for placebo-controlled
surgical trials
It is a requirement for all clinical trials not only to be scientifically rigorous and ethically sound, butalso to be conducted in accordance with all relevant regulatory requirements. This is particularly the
case for placebo-controlled surgical trials, for which regulatory constraints may be especially stringent,
given the invasive nature of the placebo and the complex nature of the trial design. Where available,
regulatory guidance outlines the circumstances under which placebo-controlled surgical trials are
permissible and any extra conditions imposed on the conduct of such a design. The most widely used
regulatory guidance to date has been that of the American Medical Association (Chicago, IL, USA),37
which outlines that surgical placebo-controlled trials are permissible when existing surgical procedures
are being tested for efficacy or where there is no known surgical treatment currently available or
non-operative treatment options are known not to be acceptable to patients. However, it highlights
that additional safeguards must be included in the consent process if a placebo procedure is to be used.
Regulatory guidance has been noted to have two main roles for those designing placebo-controlled
trials in surgery: (1) to constrain the inappropriate use of placebo surgical controls and (2) to justify the
acceptability of a placebo surgical design under key circumstances. A more detailed description of this
dual purpose to regulatory guidance can be found in the report of the KORAL (Knee Osteoarthritis: Role
of Arthroscopic Lavage) trial38 (a proposed surgical placebo-controlled trial of knee arthroscopic lavage).
A scoping review of relevant international regulatory guidance was undertaken. This involved a
systematic electronic search for published regulatory guidance, an augmented text search of major
medical/surgical association websites (including electronic codes of practice/ethics codes), a review of
other known statements (e.g. the RCS of England statement on placebo surgery trial39) and direct
contact with surgeons in different jurisdictions.
Most medical/surgical associations had only very generic references to the design and conduct of
clinical trials. Where placebo controls are mentioned, they are primarily discussed in the context of
placebo drug trials. The American Medical Association,37 the Canadian Medical Association (Ottawa,
ON, Canada),40 the German Medical Association (Berlin, Germany)41 and the RCS of England39 did,
however, explicitly discuss surgical trials (and surgical placebos). In addition, the New Zealand Medical
Association (Wellington, New Zealand)42 described the circumstances under which placebo controls
could be used for testing ‘therapeutic procedures’ (which could encompass surgical procedures).
Regulatory guidance suggests that the use of a surgical placebo control needs to be carefully considered
on a case-by-case basis. The risk of subjecting participants to a potentially harmful placebo intervention
needs to be weighed up against the expected individual and societal benefits of undertaking the trial.
Where the balance of risks to benefits is deemed to be acceptable to clinicians and patients, regulation
suggests the following:
l The use of a surgical placebo is justifiable to test the efficacy of a new surgical intervention.
l The use of a surgical placebo is justifiable to test the efficacy of existing surgical interventions
(where doubts exist over benefits and where evidence of efficacy is lacking).
l The use of a placebo surgical control is not considered appropriate when a standard treatment that is
known to be efficacious and acceptable to the patient exists or where the surgical technique under
evaluation represents only a minor modification of an existing evidence-based surgical procedure.
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In the circumstances where surgical placebos are deemed justifiable, regulation further suggests that:
l triallists should formally document the justification for their use of a placebo surgical control
l triallists rigorously consider the composition of the proposed placebo procedure and ensure that
components are well specified and explicitly documented
l triallists explicitly consider the level of risk to the patient from the placebo and outline ways in
which risks can be mitigated
l trials with a placebo surgical control arm provide enhanced information to participants and consider
any expanded consent needs
l trials with a placebo surgical control arm consider enhanced monitoring with an option for early
termination should the active intervention show effectiveness at any stage before the end of
the trial.
THE CURRENT REGULATORY REQUIREMENTS FOR PLACEBO-CONTROLLED SURGICAL TRIALS
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Chapter 5 Systematic literature review
update for placebo-controlled surgical trials
As preparatory work for the workshop, we undertook a systematic review of previously conductedsurgical RCTs in humans. This was an update of a previous review by Wartolowska et al.5 until
December 2017. (Although the review search strategy was completed in December 2017, we are not
aware of substantive changes in the literature since that time.) The complete methods, findings and
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) inclusions have been
published separately.43 The work is summarised here.
Data were extracted for trial characteristics and methodological areas of interest, including rationale
for the use of placebo interventions, patient information, intervention standardisation and fidelity,
delivery of co-interventions and anaesthesia, trials offering treatment interventions to patients
allocated to placebo and how risk is minimised because of the invasive placebo.
Of 1864 newly screened articles, 50 were included (resulting in 96 RCTs in total). A large number of
trials were gastrointestinal based (n = 40, 42%) and evaluated minimally invasive luminal endoscopic
interventions (n = 44, 46%). Two-thirds of trials (n = 65, 68%) randomised fewer than 100 patients and
approximately one-third of trials were conducted at a single site (n = 31, 32%).
Rationale for use of a placebo intervention
Most trials did not provide an explicit rationale for using a placebo intervention. Some trials discussed
the need to quantify potential placebo effects (n = 27, 28%)13,44–69 and the role of placebo interventions
in reducing bias (n= 9, 9%).13,45,50,61,65,67,70,71 Using a placebo intervention to elucidate the mechanism of
treatment action was seldom explicitly reported. However, 10 articles (10%) acknowledged that there was
uncertainty as to which treatment components were responsible for the mechanism of action.13,50,53,63,69,72–76
Patient information
Eleven trials8,13,44–46,63,70,72,77–79 (11%) reported details of placebo-specific information given to patients.
Three trials72,77,78 specified that the placebo surgery would not treat the patient’s condition. In contrast,
one trial79 informed patients that the placebo might improve symptoms. Four trials13,44,45,63 did not use
the term ‘placebo’ in patient information, with three of these trials instead describing the characteristics
of both treatment and placebo procedures.13,44,45 The remainder informed patients of the ‘blinded’
nature of the study. Two trials46,70 reported that patients were informed that they might not receive the
treatment intervention.
Intervention standardisation and fidelity
Attempts to standardise interventions were reported in seven trials47,48,78,80–83 (7%). Four trials47,48,80,81
were delivered in accordance with a standardised protocol. One trial82 agreed a standard approach by
consensus with participating investigators. One trial83 achieved standardisation by ensuring that all
interventions were delivered by one clinician. One trial78 said that a protocol ‘was discussed in the
minutest detail to ensure that it would be adhered to in a similar manner’, although no specific detail
of intervention delivery was given.
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Four trials47,49,78,82 (4%) reported strategies to monitor the delivery of interventions (fidelity), including
videotaping (n = 3)47,49,78 and ‘monitoring of adherence to technique by the study chairman’ (no further
details given).82
Delivery of co-interventions and anaesthesia
Pre-, peri- and postoperative co-interventions were reported in 45 (47%),45,47,48,50,51,55–64,67,71,73,74,76,78,79,82,84–105
31 (32%)13,48,50,51,55–57,59,60,62,67,71,73,74,76,81,83,85,92,94,99,106–115 and 64 (67%)8,45,46,48–50,54–64,66,67,69,70,72–75,77–79,83,84,
87,88,90–96,98–102,105–107,111,112,115–128 trials, respectively, with details being matched between the treatment and
placebo groups in 42,45,47,48,50,51,55–63,67,71,73,74,76,78,79,82,84–93,95–102,104,105 2713,48,51,55,56,59,60,62,67,71,73,74,76,81,83,
85,92,99,106,108–115 and 618,13,45,46,48–50,54–64,66,67,70,72–75,77,78,83,84,87,88,90–95,98–102,105–107,111,112,115–121,123–128 trials, respectively.
Anaesthesia protocols were matched between groups in 64 (67%) RCTs.8,13,45,46,48,50–54,56,57,59,60–62,64,66,67,
69–71,73,76,78,79,81,83,84,86,88,90–95,97,98,100,102–104,106,107,109,111,112,114,116,121–124,126,127,129–135
Trials offering the treatment intervention to patients allocated to placebo
Forty-three (45%) trials45–49,51,54–56,58,59,61,62,64,66,68–71,73–75,77,78,84,85,88–90,95,97,99,107,109,111,112,114,119,121,122,124,125,132
reported that the treatment intervention was offered to patients in the placebo group.
Seven trials59,73,74,85,109,112,119 were formal crossover trials and one112 had a four-group trial design
that randomised the order of intervention delivery. Rationales were given by 16 (37%)
trials.48,55,56,58,61,62,64,68,69,73,75,78,85,95,112,122 This included if patients had continuing symptoms
(n = 7)48,55,56,62,69,78,122 and for ethics (n = 5)62,68,75,95,122 and methodological reasons (n = 3),62,85,112
such as reducing the likelihood of patients seeking treatments outside the study.
Minimisation of risk
The degree of operator skill was reported in 22 trials (23%),13,47,50,51,55,59,69,70,74,78,79,83,85,91,94,99,100,105,110,121,123,128
independent data monitoring was reported in 28 trials (29%)13,45,46,52,55,57,60,61,68,69,71,72,78,82,84,97–100,103,104,
106,113,114,121,125,128,136 and an unblinding protocol was provided in one study.84
Ninety-six placebo-controlled surgical trials were identified.8,13,44–79,81–83,85–138 Most were small
(< 100 patients), focusing on minimally invasive endoscopic techniques. Quantifying placebo effects
was the most common reason given for using placebo interventions. The information provided
to patients was variable. A small number of trials reported minimal information about standardisation
and fidelity of interventions. Two-thirds of trials matched anaesthesia protocols between the treatment
and placebo groups and nearly half of the trials offered treatment to placebo patients.
Reporting of placebo surgical RCTs is limited. Specifically, there is a need for clearer rationales for
placebo use, patient information provision, standardisation and fidelity of interventions and the use of
co-interventions. Standardised reporting guidelines may be useful. In addition, consideration for how
to minimise risk and whether or not patients in the placebo group should be offered the treatment
intervention is necessary.
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Chapter 6 Ethics considerations for
placebo-controlled surgical trials
Some of the text in the following section is reproduced with permission from Hey et al.139 Reprintedby permission from Springer Nature, Monash Bioethics Review, Hey SP, Weijer C. What questions
can a placebo answer? Monash Bioeth Rev 2016;34:23–36. Copyright 2016.139
Unlike patients treated in routine clinical practice, participants in research are exposed to risk primarily
for the benefit of others.140 It is this feature of research that drives the need for the ethics protection
of participants. The use of placebo controls in RCTs in surgery illustrates this well.11,141 When surgical
interventions that lack an evidence base are used, there are compelling scientific reasons to evaluate
them in comparison with a placebo control. However, should participants be exposed to the risks of a
placebo surgical intervention that lack the presumptive causally effective element? On the surface, at
least, such participants are being exposed to all of the risks of surgery, with none of the benefits.
Empirical research indicates that key stakeholders believe that placebo-controlled surgery trials can
be ethically defensible. One study142 found that a majority of the doctor respondents believed placebo
controls to be necessary and such trials to be ethically permissible, although there was less agreement
about the permissible degree of invasiveness and about the appropriateness of open trials. Another
study143 found that, despite some initial misgivings, researchers also accept the rationale for placebo
controls. Patients’ views appear to vary, as studies involving patients both with and without Parkinson’s
disease suggest.144 Patients without Parkinson’s disease appear more willing to participate in such
research directed at this condition than those with the condition. This may be associated with members
of the latter group having adapted to the condition, the personalities of the different respondents or
the relative ignorance of those in the former group.144 However, patients with Parkinson’s disease have
endorsed placebo trials, especially once educated about such trials.144 Another study145 found a small
majority of such patients to be in favour. This was associated with their support for research generally,
which indicates a need for potential participants to trust in the research endeavour and in the
researchers themselves.145
To earn the trust of participants, it is important that placebo trials conform to acceptable ethics standards.
The Belmont Report146 outlines internationally accepted ethics principles for human participants research:
(1) beneficence, (2) justice and (3) respect for persons. The principle of beneficence requires researchers
to ensure that the benefits and harms of study participation stand in reasonable relation. The principle of
justice concerns the fair distribution of the benefits and burdens of research. This means that researchers
should ensure adequate protections for vulnerable participants and that the results of medical research
should benefit society broadly. Finally, the principle of respect for persons enjoins researchers to take
seriously the autonomous choices of participants and to protect those participants who lack the capacity
to make their own decisions.
The use of any kind of placebo in research raises an ethics tension between the researcher’s duty of
care to those participating in the trial and society’s interest in scientifically valid medical research. The
reason for this is that, although the use of a placebo control may be required for a study to provide a
scientifically valid answer to a particular research question, it is not immediately clear how the use of
placebos can be compatible with the ethics principles articulated in The Belmont Report.146 Therefore,
how can one reconcile the use of placebos in surgical trials with ethics principles?
Placebo surgical control for a randomised trial aligns with the principle of beneficence, provided that
the risks are considered and reasonable and potential benefits exist.11 A component analysis can be
used to determine the ethical acceptability of any potential benefits and risks of a trial.147 In such an
analysis, therapeutic procedures within the intervention must be considered separately from any
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non-therapeutic procedures. This clear disconnect is not always possible, as a placebo surgical
intervention may have added physiological effects, despite lacking the critical surgical element.
Therefore, any surgical placebo control usually includes both warranted therapeutic and
non-therapeutic procedures.
Therapeutic procedures (e.g. drugs or surgical interventions) must fulfil the ethics requirement of clinical
equipoise. Clinical equipoise is defined as a state of ‘honest, professional disagreement among expert
clinicians about the preferred treatment’.148 This disagreement (or uncertainty) is best understood as
grounded in absent, preliminary or contradictory evidence regarding the safety and effectiveness of a
treatment. The point is that, if equipoise obtains, then it does not matter which trial arm the participant
is placed into. Given the state of knowledge at the beginning of the trial, both arms are deemed to be
broadly consistent with competent medical care.147
Non-therapeutic procedures (e.g. non-clinically indicated questionnaires or blood draws) must fulfil
two different standards.147 First, the harms posed by the intervention must be minimised and
consistent with sound scientific design. Second, the risks posed by the non-therapeutic intervention
must be outweighed by the value of the knowledge generated. The first standard asks us to consider
whether or not the risks are necessary and the second standard asks us to consider whether or not
the risks are proportionate.
Placebos in surgical trials comprise both therapeutic and non-therapeutic elements.149 Insofar as the
surgical placebo is a therapeutic intervention, it is best regarded as a no-treatment intervention, given
that it lacks the presumptive causally effective element of the surgical intervention. No-treatment
interventions are compatible with clinical equipoise when:
1. there is no effective treatment for the condition;
2. the trial population is enriched for treatment-resistant patients;
3. the study is a test of an add-on treatment versus placebo and all patients receive at least standard
of care;
4. treatment exists, but non-treatment is still consistent with competent care; or,
5. the effectiveness of the standard of care has been called into question either by new evidence or by
doubts about the supporting body of existing evidence.
Reprinted by permission from Springer Nature, Monash Bioethics Review, Hey SP, Weijer C.
What questions can a placebo answer? Monash Bioeth Rev 2016;34:23–36. Copyright 2016139
The last criterion is particularly relevant to the assessment of surgical procedures in common use.
When the evidence base supporting a procedure in common use is poor, such as for arthroscopic repair
of injured shoulders, the use of a placebo control is consistent with clinical equipoise.
The ethical principle of justice requires that researchers ensure that adequate protections are in place for
vulnerable participants. Vulnerability may be defined as an increased risk of being wronged in research,
where wrongs encompass autonomy, welfare and justice wrongs.150 Persons who are unable to provide
informed consent for participation in a surgical trial are at risk of an autonomy wrong. Generally, their
participation is permissible only when (1) the study hypothesis requires their inclusion, (2) surrogate
consent will be obtained from a legally authorised representative and (3) study participation involves
no more than minimal risk. When surgical placebos involve procedures such as an incision, anatomical
dissection, insertion of an arthroscope into a joint and anaesthesia, they will pose risks that predictably
exceed those of the daily life of healthy persons. In such cases, the inclusion of persons who cannot
consent to research participation, including children and incapable adults, is impermissible. Moreover,
justice might also require, where a trial establishes the utility or success of a particular intervention, that
this should be provided to all of the trial participants. This was certainly the view advanced by researchers.143
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Finally, can the principle of respect for persons be satisfied in placebo-controlled surgical trials?
Surgical trials with a placebo control are inherently complex studies and clearly conveying to prospective
participants what is at stake is a challenge. Empirical research reveals that researchers are, perhaps
unsurprisingly, well informed about placebo designs and their rationale.143 Patients’ understanding appears
to vary. The same research suggests that some would be willing to participate because of disease severity
or desperation (due to a lack of effective treatment or experimental interventions being restricted to
trial participants). The researcher queries whether or not participation on such bases is sufficiently
voluntary and, therefore, autonomous.145
Employing a rigorous informed consent process can help to satisfy concerns about autonomy. Naturally,
the scientific validity of a placebo-controlled study will require that participants are blinded to treatment
allocation. When participants are blinded, respect for persons requires that they be informed of the
treatment that they received at the end of the study.
One obstacle to obtaining valid informed consent to research participation is the so-called therapeutic
misconception, whereby research participants systematically misunderstand research elements,
such as randomisation or placebos (whose purpose is solely to further the ends of science) as being
designed to benefit them directly.151 Qualitative research has found that a majority of individuals
with Parkinson’s disease and their relatives would wish to be in the active treatment arm of a placebo-
controlled surgical trial, as they believe this means that they would be most likely to benefit.145
This might suggest a lack of understanding of trials.145 Just as component analysis requires the clear
separation of therapeutic and non-therapeutic procedures in a trial for benefit–harm analysis, so too
must informed consent clearly identify which procedures hold out the realistic prospect of direct benefit
and which are performed to further science only. Inter alia, it is important that surgical placebos are
not described in therapeutic terms, such as ‘treatment’, ‘active’ or ‘diagnostic’, when there is no clinical
indication for the placebo procedure.
As some placebo-controlled surgical trials pose an unusually high degree of non-therapeutic risk, additional
protections may be indicated. A variety of techniques have been shown to enhance comprehension in
informed consent for research, including enhanced consent forms (i.e. simplified forms developed by an
interdisciplinary team involving end-users) and additional discussion time.152 Testing research participants’
understanding of consent information is a useful means to document understanding.
Key ethics messages
l Placebo controls may be used in RCTs of surgical interventions provided that there is a strong
scientific and ethics justification for the study.
l Clinical equipoise must be obtained among the study arms. Clinical equipoise may permit a placebo
control when a surgical intervention is widely used but lacks an evidence base.
l The non-therapeutic risks of a surgical placebo can be justified only if (1) the study question cannot
be answered with a different design and (2) the risks are outweighed by the importance of the
knowledge to be gained.
l Generally, surgical trials with a placebo control may not enrol children or incapable adults unless
the risk to the participants can be demonstrated to be minimal.
l In the informed consent process, surgical placebos should not be described in terms that may
unwittingly lead participants to believe that they are clinically indicated.
l Informed consent procedures may be augmented with enhanced consent forms, additional
discussion time and testing of participant understanding.
l Participants should be informed of the intervention to which they were allocated when the study
is complete.
l Where a trial establishes the utility or success of a particular intervention, the intervention should
be provided to all the trial participants.
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Chapter 7 Design of placebo-controlled
trials in surgery
Some of the text in the following chapter is reproduced with permission from Beard et al.12Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C,
Cuthbertson BH, et al., Considerations and methods for placebo controls in surgical trials (ASPIRE
guidelines), pp. 828–38, Copyright (2020), with permission from Elsevier.12
There are several generic trial design issues that have a particular importance in the context of
surgical placebo trials, including the content of the intervention, the choice of comparison arm or
arms, whether to use a two- or three-arm trial design (with related multiplicity consideration),
achieving sufficient statistical precision and the consideration of risk. These inter-related topics are
considered below.
Designing invasive placebo interventions: content of the intervention
The design and content of the placebo are important aspects of placebo-control methodology in
surgical trials. As part of this work, we undertook an in-depth review and extension of a previously
published surgical taxonomy to allow the characterisation and optimisation of a surgical placebo.
The work has been written up in detail separately.15
In summary, the process involves deciding what aspects of the treatment intervention need to be
delivered as part of the placebo, providing a framework to enable its adequate description. Equally,
it is important to describe what parts of the intervention can or need to be omitted (i.e. identifying and
removing the ‘critical surgical element’) (see Chapter 2). The choice involves consideration of any risk to
patients by addition or omission of components and any strategies required to ensure that the placebo
sufficiently mimics the treatment in question.
The work, led by Cousins et al.,15 provides a comprehensive framework to deconstruct the surgical
intervention into its component elements. This allows the critical surgical element to be identified and
removed to generate the placebo. The resulting DITTO framework consists of five stages (Table 3).
This newly developed framework can help in the design of high-quality RCTs and to standardise
intervention content.
TABLE 3 The DITTO schema15
DITTO stage Description
D Deconstruct treatment intervention into constituent
components and co-interventions
I Identify critical surgical element(s)
T Take out the critical element(s)
T Think risk, feasibility and role of placebo in the trial
when considering remaining components
O Optimise placebo to ensure effective blinding of
patients and trial personnel
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The intervention group should always represent the surgical procedure being studied, but the level of
standardisation of the surgical technique can vary according to the aims of the study design [i.e. where
the study lies on the spectrum of explanatory (tightly controlled) to pragmatic (usual care, often with
some differences between surgeons, but with greater generalisability)]. The surgical intervention should
also take account of adjunct treatments, such as rehabilitation and medical treatment.
Comparisons and control groups in placebo-controlled surgical trials
At its simplest level, two basic alternative trial designs have been proposed for placebo-controlled
trials: (1) a two-arm comparison of placebo with active intervention and (2) a three-arm trial that has
the same two arms supplemented by a third, no-treatment, arm. The surgical equivalence is illustrated
by the FIMPACT (Finnish Subacromial Impingement Arthroscopy Controlled Trial)153 and CSAW trials.13
The two-arm study is a relatively straightforward proposition and is a direct evaluation of the effect of
inclusion of the critical or active surgical component of the procedure. The difficulties surrounding this
comparison involve patient consent and equipoise (see Chapter 8).
The three-arm trial, with inclusion of a no-treatment arm (for a three-way comparison), does add
complexity, but can be a particularly useful design to track and compare against natural history/recovery.
It also can provide information for quantifying the scale of potential placebo effect for the procedure.
However, the three-arm (or more) trial can be particularly challenging in terms of both analyses and trial
conduct. One of the main challenges is obtaining parallel start times for the intervention in all groups.
For various reasons, intervention can be delayed under some health-care systems (including routine
waiting times for receiving surgery within the clinical setting in some health-care systems). By definition,
‘no treatment’ is never delayed and there is also the possibility of ‘crossover’ to a more active intervention
group during the trial, either for rescue or because of lack of benefit.
In reality, placebo-controlled surgical trials offer several possibilities for the content of the control
group, depending on the intervention and the research question. The pros and cons of each control
group option are listed below. Although in some circumstances many comparison control groups
may be desirable, this must be weighed against the logistics and cost of a multiarm trial, along with
the complexity of analysis and difficulty with interpretation of multiarm studies, which may provide
complex and mixed messages for the reader and, therefore, affect the ability to change practice.
Altogether, there are four possible control groups (arms) with different content for a surgical placebo
trial, and each is listed below. The SUcceSS (SUrgery for Spinal Stenosis) trial,154 which tested spinal
canal decompression by laminectomy (for spinal stenosis), will be used as the exemplar.
High-fidelity placebo surgery
High-fidelity placebo surgery is placebo surgery that contains all elements of the surgical procedure,
but with the critical element removed (as discussed, see the Scientific summary and Chapter 3, The
psychological aspects of placebo). For a trial testing spinal canal decompression, this would involve
anaesthesia, a skin incision and full muscle dissection, but not the removal of bone to decompress the
spinal canal. Other intraoperative and postoperative care would be identical to the intervention group.
The advantage of using this comparator is that it tests the effect of the active component of the
surgery (decompressing the spinal canal) and tightly controls for all other factors. The disadvantage is
that it may carry some benefit itself (e.g. through denervation of the posterior elements of the spine),
such that if the two groups are similar in effectiveness then this does not tell us if both interventions
are effective or if both are ineffective. The content of the placebo treatment and similarity to the
intervention should be considered both in terms of fidelity and the DITTO framework.
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Low-fidelity placebo surgery
The lowest fidelity is a placebo surgery with no or minimal intervention (see the Scientific summary and
Chapter 3, The psychological aspects of placebo). This has been called ‘sham’ in the past, although, as
previously stated, this term is not helpful for recruitment purposes. It may, for example, involve a skin
incision only. The advantage of using this comparator is that it minimises the risks associated with
placebo surgery by minimising the extent/invasiveness of the surgery. It also tests more of the overall
surgical procedure (e.g. muscle dissection and decompression) and not just the critical element. The
disadvantage is that it does not test the critical element in isolation, as a high-fidelity comparison
might do. A further issue, as potentially observed in trials such as SUcceSS,154 is the potential for
unblinding with a low-fidelity model. Difference in surgical duration, pain/discomfort after surgery and
postoperative care could be different between groups and the risk of unblinding is high. A low-fidelity
placebo surgical intervention should not be confused with non-surgical care.
Best non-surgical care
Best non-surgical care has the advantage of testing the entire surgical procedure and of reflecting the
real-life alternatives (surgery vs. best non-operative care). The disadvantage is that it does not allow
testing of any direct or placebo effect of non-critical aspects of the procedure, including patient
expectations and concomitant treatments.
No treatment
No treatment has the advantage of measuring the natural history of the condition without new
treatment and is an important control group when ascribing improvement in any of the other groups to
the intervention received (e.g. it would test if best non-operative care is superior to no care). This has
the disadvantage of not allowing for improvements potentially due to placebo, concomitant treatment
or non-operative care. It is important to note that a ‘no-treatment’ group, in this context, is really no
surgery or ‘no additional treatment’, as patients are allowed to continue with existing non-surgical
modalities, such as medication, albeit in a regulated and usually monitored way.
Analysis features in the design of surgical placebo-controlled trials
A further challenge related to the three-arm trial is the issue of multiplicity of comparisons.155 Typically,
pairwise comparisons would be considered the most informative (allowing direct contrasts and
quantification of the treatment effect). The three-arm design, unlike the two-arm design, offers options
with the associated potential for formal statistical adjustment for multiplicity (i.e. various approaches
could be adopted). Some authors have provided compelling arguments not to penalise different
comparisons that relate to different research questions.155 In the context of surgical placebo control, it
raises the issue of whether or not a surgical placebo intervention is considered a valid interventional
option in its own right. In terms of multiplicity and wider considerations, is the contrast of the surgical
placebo intervention and no treatment a valid one to undertake?
In the context of surgery, compliance with treatment allocation is another concern for placebo-controlled
studies, given the potential explicit or implicit preferences of surgeons. This potential lack of equipoise
and its effect on trial conduct should be considered at the design stage.
Last, a trial design issue within the context of placebo-controlled surgical trials is the legitimate concern
about whether or not these trials are of sufficient size to identify the meaningful effect. A recent systematic
review43 identified the median trial size to be small, with only 65% of all studies randomising > 100 patients.
Only a handful of trials have had > 200 participants in the surgical arms.When such a sample size is
translated to target differences that can be detected under standard conditions (i.e. two-sided significance
level of 5% and statistical power of 80% or 90%), only large effects can be confidently be detected.
Offsetting this concern is perhaps the general expectation that, at least for most of surgery, the benefit
of the active intervention should be large enough to justify the risk. However, such considerations do
reaffirm the need to for care in the choice of outcomes and the primary outcome in particular.
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Is placebo intervention risky and how to mitigate risk
The ethics arguments previously presented on the use of placebo surgical controls highlights the need
for mitigation of potential risk from placebo interventions. There are opposing views on the degree of
risk for surgical placebo interventions. Wartolowska et al.5 showed that trials (albeit in endoscopic or
minimal access interventions) that included a placebo surgical control had no greater risk than other
treatment or control groups. Although work from the German Society of Surgery (Berlin, Germany)
showed that the frequency of serious adverse events was comparable between true intervention and
placebo, they expressed concern that trials of more invasive placebo interventions might entail
a greater risk for study participants.6 The ORBITA (Objective Randomised Blinded Investigation with
optimal medical Therapy of Angioplasty in stable angina) study in interventional cardiology is a good
example of a study in which the frequency of adverse events was higher in the placebo group than in
the normal treatment group.45
Assessing risks of a placebo surgical control, especially in relation to fidelity, is complex and difficult to
quantify. Inert treatments, such as low- or minimum-fidelity surgery, may seem to have less risk than a
surgical procedure with higher fidelity (in which more tissues may be involved), but this simple model
may not hold. For example, those undergoing a placebo surgical procedure, despite a priori higher
risk, may still experience apparent benefit, although not achieved through any known (or theoretically
causal) mechanism. Similarly, the apparent ‘safety’ of a minimum fidelity procedure, in which there is
little tissue damage, is tempered by the risk of anaesthetic complications. It should be remembered
that the risk of any anaesthetic complication or surgical site infection after incision will apply to all
groups undergoing surgery and similar anaesthesia (including those in the placebo arm). Discussion
should include the situation when the risks of a surgical treatment in a ‘low-/minimal-fidelity’ placebo
surgery group can potentially outweigh the benefits of the study findings to society. This can be
difficult to reconcile. It is not clear how much risk is ‘too much’ and when a placebo surgery control
group trial is ‘not worth it’. It remains a complex area and will depend on individual procedure risk
plus routine surgical risk (e.g. anaesthetic), with consideration of the perceived capacity to benefit
from the specific surgery in question.
Previous literature has suggested various strategies for risk mitigation, including:
l restriction of eligible patients to those with a low clinical risk profile (e.g. restriction to American
Society of Anesthesiologists grades 1 and 2)
l reducing the invasiveness of the surgical placebo (this forms part of the balance between fidelity
and risk alluded to above)
l review of the form of anaesthesia used for the placebo procedure
l use of experienced surgeons only who are familiar with the surgical intervention under evaluation
l enhanced monitoring with oversight committees.
Therefore, it is important that all means of risk mitigation are explicitly outlined before undertaking a
placebo-controlled surgical trial. When the overall risk of any placebo surgical control is deemed to be
unacceptably high (despite all possible risk mitigation strategies), a placebo-controlled design should
not be used. However, without a sufficiently robust trial, the surgery may continue unabated, with all
patients continuing to be subjected to all risks related to the procedure. In this situation, the riskier the
procedure then the more urgent the need for a sufficiently robust (placebo-controlled surgical) trial.
If the use of a placebo control is scientifically justified then the next step is to mitigate the risk
of this incomplete surgery by reducing its invasiveness as far as possible. As previously stated, an
unintentional unblinding should be guarded against to avoid loss of the methodological advantages
of a placebo comparator (and, therefore, making its use and the whole trial futile).
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Chapter 8 Trial conduct and recruitment
in surgical trials
Some of the text in the following chapter is reproduced with permission from Beard et al.12Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C,
Cuthbertson BH, et al., Considerations and methods for placebo controls in surgical trials (ASPIRE
guidelines), pp. 828–38, Copyright (2020), with permission from Elsevier.12
Patient information for placebo-controlled surgical trials
The ethics and legal requirements for potential participants to provide informed consent for inclusion
in a randomised trial are well established. These include both verbal and written information explaining
the purpose of the trial, research procedures, risks and benefits, end-of-trial provisions, source of
funding, conflicts of interest, and institutional affiliations.156 Potential participants should be made aware
of refusal rights and the ability to withdraw their consent at any time.156,157 This routine regulatory
guidance does not contain explicit requirements for placebo surgery trials. Both the European Medicines
Agency’s Guideline for Good Clinical Practice E6 (R1)158 and the US Food and Drug Administration’s
guidance for informed consent159 information sheets contain only general requirements about placebo
trials, mostly designed for drug trials and not placebo-controlled surgical trials.
Section 2 in this guidance158 on the current regulatory requirements for placebo-controlled surgical
trials highlights the suggestion from several medical associations that trials with a placebo surgical
control arm should provide enhanced information to participants and consider any expanded consent
needs. However, the details of how this should be operationalised in terms of exacting information for
placebo-controlled surgical trials has not been specified. There are some broad items of content
information for placebo-controlled trials than could be considered:
A full description of the placebo-surgical procedure;
A statement that although benefit might result from a surgical placebo procedure, there is no known
mechanism by which the placebo surgery should result in direct benefit for the index complaint;
Recognition that the use of the procedure is for research purposes;
The need to avoid language in the consent process that might unwittingly promote any
therapeutic misconception;
Possible risks or discomforts linked to both the index and the surgical placebo procedure.
Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C,
Cuthbertson BH, et al., Considerations and methods for placebo controls in surgical trials
(ASPIRE guidelines), pp. 828–38, Copyright (2020), with permission from Elsevier12
It is, however, important to recognise that these items may not be applicable to all placebo-controlled
surgical trials and will be dependent on the nature of the placebo. For example, when considering a
placebo with no fidelity (i.e. a sham procedure) (see Table 1), it would be necessary to inform potential
participants that allocation to the placebo may not result in personal benefit. The converse, a high-fidelity
placebo, may confer some potential benefit on the participant and so needs to be framed accordingly.
The fidelity spectrum for placebo controls will be key in considering what information should be included
in the information provided to and shared with potential trial participants. This should help to address
concerns over the therapeutic misconception in trials of this type.
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TRIAL CONDUCT AND RECRUITMENT IN SURGICAL TRIALS
In addition to the information provided to potential participants on the placebo comparator in surgical 
trials, it is important to consider how to present information on the surgical intervention being 
evaluated to promote informed choice about participation. The surgical intervention will probably be 
the current standard of care and what the patient will receive should they chose not to participate in 
the trial. The information provided on the risks of the surgical intervention needs to be considered 
equally with regard to the placebo comparator. For example, the risk of a general anaesthetic for both 
the surgical intervention and the placebo should be considered alongside the risk of surgical site 
infection, especially when the placebo comparator is of low fidelity.
Methods to specify core content for patient information for trials while working with potential 
participants are available.160 These opportunities for the co-production of information in advance of 
the trial will be key for developing patients’ information for placebo-controlled surgical trials that is 
fit for purpose. In addition to the core content, considering how the information is provided to enable 
support for decision-making is also important. Rogers et al.161 have proposed the use of decision 
support tools (namely decision aids) to help potential participants deliberate over their participation 
in placebo-controlled surgical trials by improving research literacy and attending to potential concerns 
over therapeutic misconceptions. There is preliminary evidence that the medium (e.g. verbal, written, 
audiovisual) and who (e.g. the surgeon) presents the information may also make a difference to potential 
trial participants in placebo-controlled surgical trials.162
As well as information provided to potential trial participants at the point of considering participation in 
a trial, written (and often verbal) information is provided throughout the trial in the form of follow-up 
questionnaires, newsletters and trial results. Each interaction with a participant requires consideration 
regarding the information being shared with them and how that may have an impact on aspects of the 
placebo-controlled surgical trial that are important for conduct and analysis (i.e. considering the 
information continuum across the lifetime of the trial).
Maximising recruitment
Overestimation of the pool of available eligible patients is common, and especially true for placebo-
controlled surgery trials. A systematic review7 of placebo surgery trials (63 studies published between 
1959 and 2014) found that slow recruitment that was directly attributable to eligibility was a 
substantial barrier to trial completion. It was found that approximately five people needed to be 
screened to identify one eligible person. In an Australian placebo-controlled trial50 of vertebroplasty, 
performed before the procedure was widely available in that setting, only 34% (of 468 people screened) 
were eligible. Almost half (49%) of those found to be eligible agreed to participate.50 A recruitment 
strategy that included direct-to-consumer adverts using a range of media failed to substantially improve 
the pool of eligible people. A more focused approach to doctors who manage vertebral fractures across 
primary to tertiary care was more successful.
Recruitment into placebo-controlled trials testing treatments that are already widely accepted, available 
and affordable, despite an absence of high certainty evidence supporting their use, is especially challenging. 
Both surgeons and patients may be reluctant to accept a 50% chance of placebo, particularly when placebo 
involves invasive surgery. In any case, recruitment planning of both surgeons and participants must 
necessarily start early, as it is essential to determining the feasibility of the trial.
Several recent initiatives have developed frameworks for strategic recruitment planning, and these 
highlight the need for realistic budgets and resources to support recruitment.163 At the trial design and 
protocol development phase, Huang et al.163 have highlighted that it is essential to identify and engage 
all stakeholders, ensure the relevance of the scientific question and have realistic eligibility criteria. 
Trial feasibility requires evidence-based feasibility analyses, having realistic metrics and milestones, 
and ensuring appropriate site selection and performance monitoring.
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Recruitment communication planning can strongly facilitate a trial. It involves identification and engagement
of all relevant stakeholders, clarifying treatment pathways, developing and testing tailored and creative
messages/materials, and monitoring and evaluating process and performance. The QuinteT Recruitment
Intervention system for optimising recruitment and informed consent pioneered by Donovan et al.164 has
been very successful and is based on identification of the motivators of and barriers to trial participation.
Increasingly, business models and modern marketing theory and techniques have also been used to
inform strategies for recruitment.165–167 For example, McDonald et al.166 recommends developing and
building brand values that gain prestige and legitimacy and signal worthiness of the trial; developing an
explicit market plan, including strategies for overcoming resistance; making the ‘sale’ through achieving
public buy-in, delivery of a multiaudience, multilevel message and engaging champions and change
agents; and maintaining engagement via provision of frequent positive reinforcement and facilitating
incorporation of recruitment into usual routines.166,168
Embedding recruitment intervention studies and sharing the results will also ensure advancements in
trial recruitment for placebo surgery trials, but there is currently a paucity of data in this space. For
example, a 2018 Cochrane review168 investigating strategies to improve recruitment into clinical trials
included 68 RCTs; however, none of the RCTs was a placebo surgery trial. Likewise, a review published
in 2015 included 17 trials investigating training programmes for recruiters to RCTs also failed to
identify any programmes specifically for recruiters of placebo surgery trials.169 The latter review found
that, although training increased recruiters’ self-confidence in communicating key trial concepts to
potential participants, there was little evidence that it increased recruitment rates.
Furthering our knowledge about how to optimise recruitment into placebo surgery trials, including the
information that is provided for potential trial participants and who should provide that information,
is crucial. It is well known that the preferences of patients, as well as health professionals, including
surgeons who provide the treatment, can have a decisive influence on trial recruitment:170
These questions include whether transmission of preference can be mitigated if consent is obtained by a
trained and ideally neutral recruiters; whether well-informed patients are more or less likely to accept
random assignment to; and whether or not surgeons should be allowed to restrict random assignment
to eligible patients only when personally uncertain as to which intervention would be the best option.
Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C,
Cuthbertson BH, et al., Considerations and methods for placebo controls in surgical trials
(ASPIRE guidelines), pp. 828–38, Copyright (2020), with permission from Elsevier12
Placebo-controlled surgical trials: the patient’s perspective
The patient’s perspective is crucial to the design, conduct and analysis of placebo-controlled
surgical trials. The patients’ partners gave this critical reflection:
As patients and patient representatives, it was a privilege for us to be invited to the Workshop; to
contribute but also to learn more about the fascinating world of placebo surgery trials.
The patient follows a journey: through development of symptoms, to medical consultation, enrolment in
the trial, treatment (or pseudo treatment), follow-ups, recovery (or not) and ultimately ‘unblinding’. Patients
join clinical trials for a variety of reasons and for each there may be a mixture of altruism, self-interest
and curiosity. Many patients will have reached a point where they feel desperate to find a solution to
their symptoms. Any observations about the process of recruitment are necessarily personal and anecdotal.
This said, clear and simple explanations of what participation will involve answering questions, enabling a
dialogue and, significantly, clarifying what options are open to the patient during the trial. It is obvious that
at no point should the participant feel that they were deceived about any aspect of the trial.
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All patients benefit from being informed, supported and having a good relationship with their clinicians.
It is the same for participants in clinical trials and perhaps not more or less for those in placebo surgery
trials. There must be trust and confidence not only in the lead clinician, but in the whole team administering
the trial. Some patients felt that, having had potential participation broached to them by their surgeon,
it was helpful for more detailed discussions and decision-making to take place separately, with a different
member of the team.
The ‘unblinding’ stage is a key one and it is important that patients know both when and how they can
access this information. Not all will be familiar with electronic communication and more traditional
methods, such as letters, should be offered. This also applies to the published results of their trial.
This is of great importance to participants and so it must be presented in an easily digestible form.
Any participants whose symptoms are persisting will need continued treatment and support.
Friends and family tend to be very interested in the experiences of participants and favourable reports to
them may open the door to future volunteers.
These reflections echo the conclusions from the ethics and trial literature that communication is key,
and that potential risks and benefits of participation need to be clearly laid out (as identified in Chapter 4).
Timely and direct feedback of trial results is also crucial.
Placebo-controlled surgical trials: the surgeon’s perspective
The surgeon’s position with regard to a placebo trial can be a difficult one. Surgeons who are
investigators for the study and fully believe in the utility of the placebo-control methodology often
have different perspectives from those who are simply recruiting to the trial. The recruiting surgeons
must explore and satisfy their own position of equipoise. This is not straightforward, as surgeons have
been trained to make clear-cut decisions and, as a rule, do not sit easily in a landscape of uncertainty,
especially the uncertainty that a postulate of a placebo-controlled surgical trial brings. The patient is
expecting their surgeon to express confidence and reassurance about the operation they are about to
perform, and the reason for doing it, but is told that they can be recruited to a study that questions
the very benefit of the proposed treatment. Both surgeon and patient are asked to accept that the
evidence for the treatment is insufficient and this can generate concerns for both groups. The
explanation of a control treatment of surgery that may have some risk without necessarily any benefit
is an added layer of complication to convey to a vulnerable patient.
Reconciliation of these positions can take substantial consideration. Ultimately, as the ethics literature
in Chapter 2 highlighted, the surgeon has to believe that the evidence for the intervention under
assessment is insufficient and that a placebo design is the best, or the only, way of providing the
evidence. Only then can surgeons discuss the merits and issues with a patient and recruitment be
successful and fully informed. Qualitative research in these areas can help considerably with this
process, as has been seen in the ProtecT (Prostate Testing for Cancer and Treatment) study in
urology,171 the CSAW study13 and the wider area of trials recruitment involving surgeons.164,172
There is an increasing acceptance among the surgical community that surgery and surgical intervention
requires more comprehensive and rigorous evaluation, and this is helping surgeons become familiar
with the needs for involvement and recruitment to surgical trials. It is essential that surgeons involved
in placebo-controlled trials are fully knowledgeable of the rationale, conduct and implications of these
types of studies, especially the teachings on community equipoise and uncertainty.
TRIAL CONDUCT AND RECRUITMENT IN SURGICAL TRIALS
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Placebo-controlled surgical trials: the anaesthetist’s perspective
A theme that appeared in this previous work in this field was the identification that key stakeholder
groups for such trials are broader than previously understood and that previously less prominent
stakeholder groups are very influential. An important example of this is anaesthetists.
Anaesthetists do not necessarily have major involvement in the diagnosis, prognostication or
identification of treatment trajectories and outcomes in patient groups that may be considered for
such trial methodologies (e.g. patients with osteoarthritis), but are key clinical stakeholders when
it comes to patient safety around the perioperative period. Importantly, the perioperative period is
where the greatest risk to patients lies in placebo trials and, therefore, the area where the greatest
focus comes from clinical, ethics, regulatory and other risk management stakeholders.
An interesting example of this comes from the KORAL study.38 It might be thought that anaesthetists
would consider sedation and local anaesthesia, or perhaps regional anaesthesia, to be the safest
anaesthetic techniques to use when delivering a trial intervention, as these appear on the face of it to
be relatively low-risk techniques. However, when asked, a significant majority of anaesthetists taking
part in a focus group thought that general anaesthesia with full control of the airway was the safest
procedure, and, importantly, they also pointed out that general anaesthesia would supply the highest
fidelity placebo for the proposed study intervention. According to the anaesthetists, intravenous sedation
techniques have been reported in the medical literature to be unsafe, and their own experience showed
that local anaesthesia techniques are often insufficient for surgery, with implications for both patients
and control group fidelity. These conclusions were the opposite to those drawn by the lay reviewer and
by trial team members from medical backgrounds other than anaesthesia (e.g. the surgeons), showing the
benefit of such expert engagement. Conversely, if anaesthetists are to assess the risk-to-benefit ratio in
proposed placebo surgery trials, they need to understand the potential benefit of the proposed surgical
procedures so that they can weigh this against the risks of anaesthesia from the perspective of their own
clinical expertise.
To allow such high-level engagement, anaesthetists must be integrally involved in the acceptability
phases of future proposed studies (e.g. in the design and piloting of the intervention, as well as
informing the ethics and regulatory decision-making from the perspective of patient safety).
Anaesthetists are identified as key stakeholders in all future research involving local or general
anaesthesia, as well as intravenous sedation, for placebo trials.
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Chapter 9 Interpretation of placebo-controlled
surgical trials and changing practice
The statistical analysis plan and potential results scenarios
All clinical trials should have a statistical analysis plan. This gives an a priori opportunity to review
potential scenarios for the results of the trial, what the results might mean and how this is translated into
clinical interpretation. This process is especially important for placebo-controlled trials. The complexity
of a multigroup design, perhaps with a no-treatment arm, brings about many possible interpretation
permutations (see Chapter 3, The physiological aspects of placebo). The surgery can be shown to have
more benefit than placebo or no treatment, or maybe no added benefit. A hierarchy of benefit may
be proposed perhaps with surgery being more beneficial than both placebo and no treatment.
One of the advantages of outlining the various possible results scenarios is to prepare for any clinical
conclusions and potential obstructions to change of practice (outlined below). Early consideration
of difficult commissioning decisions can be shared upfront with the surgical community conducting
the trial if the options are reported. Sudden realisation from surgical personnel that they have been
involved in a study that questions the value of an established procedure can be alarming and have
negative influences on any change of practice and acceptance of that change.
A further stage for the future might be to fully explore what the trial results might mean with all
parties before the trial has even started. The discussion around whether or not a placebo treatment
still has sufficient benefit or merit to be commissioned or provided as a treatment in itself could also
be had at this time.
Translation into change of policy and practice
Many of the placebo-controlled trials of surgery reported to date have shown no benefit of the
definitive procedure over the placebo-controlled intervention. The design is popular and used
frequently to explore treatments with suspicious efficacy and effectiveness. Bearing in mind the ethics
and academic justifications required (see Chapters 6 and 7) for a surgical placebo control, reasonable
preliminary evidence is, therefore, required to show that part or all the treatment effect of the surgical
procedure under investigation might be due to the placebo effect. As previously reported, investigation
of a treatment that has no such placebo component, or even a general belief that surgery has no
placebo effect at all (Dr Teemu V Karjalainen, Central Hospital, Finland, 2020, personal communication),
would not require a placebo-controlled evaluation.
With this backdrop and focus on established, if questionable, procedures, investigators responsible for
undertaking such trials must anticipate that any ‘no difference’ results of the trial will be disruptive to
accepted clinical care pathways and guidelines. Investigators should also expect, and be prepared for,
resistance from clinicians and patients whose beliefs and convictions are being challenged by the
findings. Such trials will also generate interest from payers (state and insurance based), press and media.
Once change is indicated, there can be a long lag between research findings and change in practice,
as exampled by trials of knee arthroscopy. In the case of knee arthroscopy for osteoarthritis, although
the original publication was in 2002,72 it took 15 years for the findings to be partially adopted, despite
several other high-quality studies replicating the findings. Similar resistance from the clinical community
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has been encountered with trials of vertebroplasty for osteoporosis50 and subacromial decompression
for shoulder pain.13 There are consistent features of the resistance and these include a belief by the
surgical community that the patients in the trial do not represent the usual population undergoing
the procedure. It is also suggested that the surgeons involved in the trial may not be sufficiently
expert in the procedure. In other words, a feeling that the trial results ‘do not apply to me and my
practice’ is commonplace. This sentiment is highlighted by the expressed views of 15 combined
surgical associations of one European country. These associations have advised that, contrary to
previous reports, the CSAW trial does not provide any new insights and there are no consequences
from the CSAW study for this country’s health system. The response in the UK was starkly different
with NHS England moving to de-implement subacromial decompression surgery by placing it on a
list of ‘ineffective’ treatments.173
The question then becomes ‘How can the challenge of effective and timely change of policy and
practice be improved?’. There are ways to facilitate, and ideally consideration of any impact should be
included in the design phase and conduct of the trial. Most importantly, this should include key leaders
in the patient groups, professional associations and clinical communities involved in delivering the
investigated treatment. If the results are likely to have global impact then consideration should be
given to involving international investigators. There should be ‘buy-in’ from patients and professionals.
As soon as results are known, further discussions and the production of joint statements are necessary.
If the implications are that the procedure will likely be performed less frequently then advice for
patients about alternative treatment is essential.
The policy-maker’s perspective
Policy-makers consist of two broad groups: (1) those who issue guidance about how health-care
interventions should be used and (2) those who commission and pay for services. In most health
systems, those who make decisions about service provision attempt to maximise the health returns
obtained for the investment [e.g. by maximising the quality-adjusted life-year (QALY) output of any
health services provided]. Evidence of value from studies employing a placebo control and the value
of any placebo effect itself may be viewed differently by each side.
Payers (e.g. commissioners in the English NHS and insurance companies in many European countries)
tend to value a QALY gain, regardless of its origin. If a policy provides a net health gain for a reasonable
price and is acceptable to patients and society, then the mechanism by which that gain occurs may not
be considered important. The health-care system is a mechanism for turning money into QALYs, and
exactly how that occurs may not be important.
Guideline generators see things differently. Producers of guidelines tend to pursue the understanding
of how a health gain is generated. There can be unease when a gain occurs through a non-specific
placebo mechanism, rather than the anatomical, physiological and psychological processes that the
intervention’s logic model presupposes. For interventions that may have a significant placebo effect,
a guideline producer would like to see robust studies that explore that effect and enable them to
separate out any placebo benefit. Therefore, the guideline producer tends to value more comparative
studies with active control or placebos, whichever is clinically more appropriate.
There are potential impacts of establishing that an intervention has a significant placebo component
contributing to the effect. First, there may be downgrading of any recommendation to use the procedure,
as it has been shown not to ‘work’. Second, the payer who may have previously willingly paid for the
procedure now follows the downgraded recommendation and declines to fund an intervention that may
be effective, albeit with a large placebo component (an unanticipated mechanism).
INTERPRETATION OF PLACEBO-CONTROLLED SURGICAL TRIALS AND CHANGING PRACTICE
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The journal’s perspective
The view expressed by journals may be best conveyed by the editorial accompanying the placebo
surgery methods paper in The Lancet:174
Writing in today’s The Lancet, David Beard and colleagues review the role of placebo controls in surgical
trials and present recommendations for their use. Over the past 10 years there has been increasing
recognition of the importance of the placebo effect, particularly how strong this effect could be for a
surgical procedure that involves high-intensity medical care, strong analgesia, and often physiotherapy.
The growing use of placebo-controlled surgical trials to re-examine common surgical procedures that
have a biologically convincing mechanism and a long history of use has led to a wave of unexpected
results. Of surgical procedures examined with this rigorous method, half were proven to be no more
effective than placebo.
The systematic debunking of many well established, definitive operations has become perhaps the biggest
story in surgical research this decade. Common procedures such as vertebroplasty and subacromial
decompression have been shown to be largely ineffective, but these procedures continue to be in common
use. Challenging current practice is difficult in many areas of medicine, particularly where there are
potential personal and commercial vested interests, including private practice. Stopping the use of a
common but debunked surgical intervention will be especially tough because the alternative is not a
newer or better intervention but often a continuation of the patient’s current treatment course. For some
of these procedures, where insurers or care commissioners have prevented surgeons from doing them, the
discourse has often centred erroneously on rationing. The argument is not really about cost-effectiveness
but rather that when robustly assessed, these procedures have been found to not be effective at all and
still risk adverse effects.
Beard and colleagues discuss the need to plan for a negative result at the outset of a trial, anticipating
the disruption that such a result produces, and creating processes to allow a transition of practice.
The responsibility for doing this lies not only with surgical researchers, but also with the wider medical
community. It is only by having the tenacious drive to question and critically assess with the most robust
studies that we can leave behind ineffective procedures and concentrate on the many areas where surgery
cures and heals.
Reprinted from The Lancet, vol. 395, Editorial. Gaining control: placebos in surgery trials, p. 756,
Copyright (2020), with permission from Elsevier174
DOI: 10.3310/hta25530 Health Technology Assessment 2021 Vol. 25 No. 53
Copyright © 2021 Beard et al. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social
Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution,
reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the




Applicants for the commission were Professor David Beard, Associate Professor Jonathan Cook,Professor Marion Campbell, Professor Jane Blazeby, Professor Andrew Carr, Associate Professor
Thomas Pinkney, Professor Brian Cuthbertson, Professor Irene Tracey, Professor Rachelle Buchbinder,
Professor Julian Savulescu, Mr Dair Farrah-Hockley and Dr Natalie Blencowe.
As part of the process of developing the ASPIRE guidelines, a 2-day workshop was held in St Anne’s
College (Oxford, UK) in December 2018. In addition to the applicants, the academic workshop
participants were Dr Jonathan Pugh, Dr Felicity Bishop, Dr Sian Cousins, Professor Charles Weijer,
Prof Richard Huxtable, Professor Jon Nicholl, Professor Pascal Probst, Professor Peter Brocklehurst,
Dr Andrew Cook, Dr Katie Gillies, Professor Freddie Hamdy, Professor Ian Harris, Dr Naomi Lee,
Professor Stefan Lohmander, Professor Amar Rangan, Professor Barney Reeves and Dr Sam Rowley.
Dr Carol Brennan and Mr Dair Farrah-Hockley kindly attended as patient representatives.
Dr Sian Cousins and Dr Natalie Blencowe kindly took detailed cross-referenced notes throughout and
recorded the workshop discussions.
Ms Katie Chegwin was responsible for the administration and organisation of the workshop, editing of
the manuscript and is thanked for her assistance.
Near-complete versions of the report were also sent to Professor Marion Campbell, Professor
Jonathan Cook and Professor Manuela Ferreira for additional review, comment and edit.
ASPIRE recommendation summary
A practical checklist that summarises the learning points from the ASPIRE guidelines and represents a
minimum standard that researchers should attain and demonstrate when designing a placebo-controlled
surgical trial is presented in Box 1.
BOX 1 ASPIRE checklist for the design and conduct of placebo surgical controls in randomised trials
ASPIRE checklist
Rationale & ethics
l Justify the scientific rationale for the use of a placebo surgical control.
l Justify how the use of placebo adheres to accepted ethical principles:
¢ Is there equipoise?
¢ Is it evaluating a novel surgical procedure in a condition for which there is no proven, effective
surgical intervention or is it evaluating a procedure in common use for which the evidence base
is poor?
l Weigh up the risk–benefit considerations underpinning the choice of a placebo-controlled design.
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Design
l Identify who the trial is designed to inform (and thus whether the inclusion of a no intervention arm is
also desirable).
l Identify the essential surgical element through adoption of the DITTO framework (using pilot and
feasibility work as appropriate).
l Outline the placebo surgical control in terms of its level of fidelity to the index surgical procedure.
l Provide a clear and detailed description of the components of the placebo surgical intervention.
l Outline how mitigation of risk of the placebo surgical control has been considered.
l Engage key stakeholders (including patients, anaesthetists, physiotherapists and primary care physicians)
in the design of the trial.
Conduct
l Avoid the use of terms such as ‘sham’ or ‘fake’ surgery.
l Engage participants in the production of the trial including patient information.
l Provide the following information in patient information leaflets:
¢ a full description of the placebo and index surgical procedure
¢ a statement that whilst benefit may accrue through undergoing a placebo surgical procedure, that
there is no known mechanism by which the placebo surgery should result in direct benefit for the
indicated complaint
¢ recognition that the use of the placebo surgical procedure is being used predominantly for
research purposes
¢ information on the possible risks or discomforts linked to the index and placebo surgical procedure.
l In patient information leaflets, surgical placebos should not be described in terms that may unwittingly
lead participants to believe that the placebo surgery brings benefit in itself.
l Ensure balance in the information provided on both the index surgical procedure and the placebo
surgical procedure.
l Consider use of enhanced processes (e.g. decision-aids) to facilitate patient understanding of the
advantages and disadvantages for them of participating in a placebo surgical trial.
l Consider use of enhanced recruitment processes (e.g. QuinteT-type approaches) to facilitate and
optimise recruitment processes.
l Consider enhanced monitoring of the trial to allow early stopping if benefit or harms clearly observed
early in the index surgical procedure group.
l Consider action and communication to the patient at the end of the trial, i.e. offer of different treatment.
Interpretation & translation
l Prepare in advance for dissemination and implementation of findings from the trial.
l Ensure early inclusion of key leaders from patient groups, professional associations and clinical
communities, systematic reviewers/guideline makers, policy makers involved in routinely delivering the
treatment under investigation.
l Consider insights from implementation science for the effective translation of trial findings into change
of practice (e.g. use of theory-informed, evidence-based strategies to address expected barriers to
behaviour change).
l Consider the implications for shared decision-making and clinical practice early – including advice for
patients about what alternative treatments are available if the implications are that it is anticipated that
the procedure will be performed much less frequently because of the trial findings.
Reprinted from The Lancet, vol. 395, Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C, Cuthbertson BH,
et al., Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines), pp. 828–38,
Copyright (2020), with permission from Elsevier.12
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Example of using the guidelines
An example is given of how the guidelines may be useful in the development and conduct of a
placebo-controlled surgical trial.
A researcher is considering a study to assess the efficacy of a new surgical treatment for knee pain
in patients with osteoarthritis of the knee (prior to arthroplasty). The team wish to demonstrate
fundamental efficacy for the treatment and are aware of the potential non-specific effects and placebo
effects of undergoing a surgical treatment. Therefore, as one option, they consider a placebo surgical
control design. They familiarise themselves by reading the background sections on placebo definitions,
placebo effect and design in these NIHR/Medical Research Council (MRC) guidelines. If the study can
be answered without a placebo surgical control, or the question does not involve fundamental efficacy
(perhaps comparative effectiveness) or lack of efficacy is already evident from studies not using placebo
(Dr Teemu V Karjalainen, personal communication), then no further placebo involvement is needed.
If placebo control remains an option, then researchers can check through the ASPIRE guidelines to
assist their decision-making. An important aspect is justification for using a placebo control, as such
designs are complex and have an ethics aspect (see Chapter 6). The team agree that the placebo and
non-specific effects are potentially large for the new intervention and may need to be accounted
for by a placebo control. Before confirming this design, other designs are considered for answering
the set research question. One alternative for exploring efficacy is a two-armed study comparing the
treatment against ‘no treatment’ (natural history). A further option is a three-armed study with both
placebo and ‘no treatment’ controls. After considering the trial conduct and recruitment aspect of
placebo designs and the ethics implications (see Chapter 8), it is felt that not offering any treatment
would be inappropriate and unsuccessful for this particular trial. Therefore, a two-armed surgical
intervention compared with placebo surgical intervention is decided.
The content of the placebo surgical intervention is then decided by breaking the surgical procedure
down into component constituents, as per the DITTO framework. A decision on the level of fidelity of
the intervention to the definitive surgery is made. This is contingent on the research question, the type
of surgery and practicalities of the surgery.
The ethics of the trial and treatment are considered, and clear patient information leaflets/consent
forms are designed on this basis, again with reference to the ASPIRE guidelines.
The conduct of the trial is designed using information and assistance highlighted in the ASPIRE guidelines.
In particular, aspects of equipoise (patient and clinician) are explored. The trial is submitted for funding.
Funding bodies may use the ASPIRE guidelines to check thoroughness and understanding of placebo
control in surgery by the research team. The trial is funded (if appropriate) and delivered.
Interpretation of the results can be made with reference to recommendations provided in the ASPIRE
guidelines. Change of practice resulting from placebo-controlled surgical trials can also be pre-empted by
reference to this document.
Submitted manuscripts for journals can be checked for completeness and understanding by editors and
reviewers using these guidelines.
Further research priorities
l Evaluation of use of the ASPIRE guidelines in making decisions about the use of a placebo-controlled
surgical trial.
l Use of the ASPIRE guidelines to assess the quality and comprehensiveness of pre-existing
placebo-controlled surgical trials.
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l Usability of the ASPIRE guidelines and evaluating their comprehensiveness.
l Further consideration of nomenclature in this area.
l Further work to establish when a placebo-controlled trial is warranted and necessary.
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Appendix 1 Workshop agenda
6 and 7 December 2018 at St Anne’s College, 56 Woodstock Road,
Oxford, OX2 6HS, UK
Medical Research Council/National Institute for Health Research state-of-the-art workshop
on methods for placebo comparator group selection and use in surgical trials
Day 1: Thursday 6 December
09.00 Registration: outside seminar room 11
Scene setting







Welcome, introduction, overview and aims (10 minutes)
Tracey: The physiology of placebo
Bishop: The psychology of placebo
Beard: Definition of a ‘surgical’ placebo, sham or part treatment?









Pugh: Overview introduction of ethical aspects
Huxtable: Ethical considerations for placebo surgical trials – part 1
Weijer: Ethical considerations for placebo surgical trials – part 2
Discussion (all)
12.45 Lunch
Design of placebo-controlled trials in surgery





Blencowe/Blazeby: Update of systematic review of placebo-controlled surgical RCTs: study
rationale, mitigating risks and methods to design and optimise the placebo intervention
Probst: Is placebo intervention risky? And how to mitigate
Brocklehurst: The place of the funder for placebo control surgical trials
Discussion (all)
15.00 Refreshments
Trial conduct: patients, personnel, recruitment
Session chairpersons: Carr and Farrar-Hockley
15.20
15.35
Gillies: Patient information for placebo surgical trials: insights from evidence and practice
Brennan/Farrar-Hockley: What the patient hears/the patient perspectives
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Hamdy: Placebo trials, the surgeon perspective
Discussion (all)
16.30 Close of day
Day 2: Friday 7 December
08.00 Breakfast: Dining Hall
Placebo trials in action and lessons learnt







Buchbinder: Maximising recruitment – vertebroplasty and arthrographic joint distension
studies
Lohmander: The content of placebo surgery – arthroscopic knee surgery
Cuthbertson: Importance of feasibility – lessons from KORAL
Cook J: Analysis plans, numbers, nuances and adjustments – lessons from CSAW
Harris: Spinal stenosis study SUcceSS – choosing the comparator and getting folk onside
Discussion (all)
11.00 Refreshments
Interpretation and changing practice





Reeves: The statistical plan and potential result scenarios
Carr: Surgical community reception, changing practice
Cook A: The policymakers perspective
Discussion (all)
12.45 Lunch
Planning and writing a guidance document
Session chairpersons: Campbell, Cook, Beard and Blazeby
13.30
13.40-15.30
Lee: The Journal’s perspective
l Planned publications and outputs
l Delphi work package
l MRC/NIHR report: structure and contents
Discussion (all) and closing remarks
1.30 Close of meeting
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